Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Palovarotene (Ro 3300074) is an agonist of nuclear retinoic acid receptor γ (RAR-γ).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 33.00 | |
5 mg | In stock | $ 68.00 | |
10 mg | In stock | $ 113.00 | |
25 mg | In stock | $ 263.00 | |
50 mg | In stock | $ 419.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 109.00 |
Description | Palovarotene (Ro 3300074) is an agonist of nuclear retinoic acid receptor γ (RAR-γ). |
In vivo | Palovarotene inhibits post-traumatic chondrogenesis and osteogenesis and mitigated trauma-induced ectopic bone formation. Palovarotene inhibits subcutaneous and intramuscular heterotopic ossification (HO) in mice. Palovarotene (1 mg/kg/day ) is given orally for 14 days starting on a postoperative day (POD) 1 or POD-5, and HO amount wound dehiscence and related processes are monitored for up to 84 days post-injury. Compared to vehicle-control animals, Palovarotene significantly decreases HO by 50 to 60% regardless of when the treatment started and if the infection is present[1]. Starting from day 1 of injury, half of the Acvr1cR206H/+ mice are treated with Palovarotene by daily gavage for 14 days and the other half received a vehicle as control. Analysis by mCT and 3D image reconstruction at day 14 shows that large HO tissue masses have formed in the targeted leg of Acvr1cR206H/+ mutant mice receiving the vehicle, but HO formation is greatly diminished in Palovarotene-treated companions by more than 80% based on bone volume/total volume quantification[2]. |
Synonyms | Ro 3300074, R 667 |
Molecular Weight | 414.54 |
Formula | C27H30N2O2 |
CAS No. | 410528-02-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 5.5 mg/mL (13.27 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
palovarotene 410528-02-8 Autophagy Metabolism Retinoid Receptor RAR/RXR inhibit Retinoid X receptors R667 Ro 3300074 R 667 Ro-3300074 Retinoic acid receptors Inhibitor R-667 Ro3300074 inhibitor